subscribeSubscribe
Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth

Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth
PR NEWSWIRE
29 Jul 2024
Share Share
Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD

Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD
PR NEWSWIRE
05 Jun 2024
Share Share
Stealth Biotherapeutics` Barth Syndrome NDA Receives Priority Review Designation

Stealth Biotherapeutics` Barth Syndrome NDA Receives Priority Review Designation
PR NEWSWIRE
07 May 2024
Share Share
Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug
Zachary Brennan ENDPTS
09 Apr 2024
Share Share
Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome

Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome
PR NEWSWIRE
08 Apr 2024
Share Share
Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide

Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide
PR NEWSWIRE
12 Jun 2023
Share Share
Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia

Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia
PR NEWSWIRE
30 May 2023
Share Share
Stealth granted FDA meeting to revive elamipretide filing

Stealth granted FDA meeting to revive elamipretide filing
Annalee Armstrong FIERCEBIOTECH
15 Jun 2022
Share Share
Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide

Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide
PRNEWSWIRE
23 May 2022
Share Share
Stealth BioTherapeutics Receives ODD for Elamipretide in DMD

Stealth BioTherapeutics Receives ODD for Elamipretide in DMD
PRNEWSWIRE
12 May 2022
Share Share